239 related articles for article (PubMed ID: 21884660)
21. Treatment of ulcerative colitis with oral mesalamine: advances in drug formulation, efficacy expectations and dose response, compliance, and chemoprevention.
Sandborn WJ
Rev Gastroenterol Disord; 2006; 6(2):97-105. PubMed ID: 16699478
[TBL] [Abstract][Full Text] [Related]
22. Maintenance of remission in Crohn's disease: current and emerging therapeutic options.
Brookes MJ; Green JR
Drugs; 2004; 64(10):1069-89. PubMed ID: 15139787
[TBL] [Abstract][Full Text] [Related]
23. Birth outcome in women with ulcerative colitis and Crohn's disease, and pharmacoepidemiological aspects of anti-inflammatory drug therapy.
Nørgård BM
Dan Med Bull; 2011 Dec; 58(12):B4360. PubMed ID: 22142578
[TBL] [Abstract][Full Text] [Related]
24. The case for using 5-aminosalicyclates in Crohn's disease: pro.
Hanauer SB
Inflamm Bowel Dis; 2005 Jun; 11(6):609-12. PubMed ID: 15905710
[TBL] [Abstract][Full Text] [Related]
25. Mesalamine in Crohn's disease with steroid-induced remission: effect on steroid withdrawal and remission maintenance, Groupe d'Etudes Thérapeutiques des Affections Inflammatoires Digestives.
Modigliani R; Colombel JF; Dupas JL; Dapoigny M; Costil V; Veyrac M; Duclos B; Soulé JC; Gendre JP; Galmiche JP; Danne O; Cadiot G; Lamouliatte H; Belaïche J; Mary JY
Gastroenterology; 1996 Mar; 110(3):688-93. PubMed ID: 8608877
[TBL] [Abstract][Full Text] [Related]
26. A randomized, placebo-controlled, double-blind trial of mesalamine in the maintenance of remission of Crohn's disease. The Canadian Mesalamine for Remission of Crohn's Disease Study Group.
Sutherland LR; Martin F; Bailey RJ; Fedorak RN; Poleski M; Dallaire C; Rossman R; Saibil F; Lariviere L
Gastroenterology; 1997 Apr; 112(4):1069-77. PubMed ID: 9097988
[TBL] [Abstract][Full Text] [Related]
27. Budesonide versus mesalamine for maintaining remission in patients refusing other immunomodulators for steroid-dependent Crohn's disease.
Mantzaris GJ; Petraki K; Sfakianakis M; Archavlis E; Christidou A; Chadio-Iordanides H; Triadaphyllou G
Clin Gastroenterol Hepatol; 2003 Mar; 1(2):122-8. PubMed ID: 15017504
[TBL] [Abstract][Full Text] [Related]
28. Current treatment for prevention of relapse and recurrence in Crohn's disease.
Prantera C; Scribano ML
Ital J Gastroenterol Hepatol; 1999; 31(6):515-8. PubMed ID: 10575572
[TBL] [Abstract][Full Text] [Related]
29. Mesalamine in the treatment of mild to moderate active Crohn's ileitis: results of a randomized, multicenter trial.
Prantera C; Cottone M; Pallone F; Annese V; Franzè A; Cerutti R; Bianchi Porro G
Gastroenterology; 1999 Mar; 116(3):521-6. PubMed ID: 10029609
[TBL] [Abstract][Full Text] [Related]
30. A randomized, double-blind, placebo-controlled trial of the oral mesalamine (5-ASA) preparation, Asacol, in the treatment of symptomatic Crohn's colitis and ileocolitis.
Tremaine WJ; Schroeder KW; Harrison JM; Zinsmeister AR
J Clin Gastroenterol; 1994 Dec; 19(4):278-82. PubMed ID: 7876505
[TBL] [Abstract][Full Text] [Related]
31. A comparison of budesonide and mesalamine for active Crohn's disease.
Lowry PW; Sandborn WJ
Gastroenterology; 1999 May; 116(5):1263. PubMed ID: 10220523
[No Abstract] [Full Text] [Related]
32. [Drug treatment of Crohn's disease].
van Deventer SJ; Tytgat GN
Ned Tijdschr Geneeskd; 1998 May; 142(21):1191-5. PubMed ID: 9627451
[TBL] [Abstract][Full Text] [Related]
33. Investigation of a High-Dose pH-Dependent-Release Mesalazine on the Induction of Remission in Active Crohn's Disease.
Suzuki Y; Iida M; Ito H; Tachikawa N; Hibi T
Drugs R D; 2016 Mar; 16(1):35-43. PubMed ID: 26883035
[TBL] [Abstract][Full Text] [Related]
34. Budesonide 9 mg is at least as effective as mesalamine 4.5 g in patients with mildly to moderately active Crohn's disease.
Tromm A; Bunganič I; Tomsová E; Tulassay Z; Lukáš M; Kykal J; Bátovský M; Fixa B; Gabalec L; Safadi R; Kramm HJ; Altorjay I; Löhr H; Koutroubakis I; Bar-Meir S; Stimac D; Schäffeler E; Glasmacher C; Dilger K; Mohrbacher R; Greinwald R;
Gastroenterology; 2011 Feb; 140(2):425-434.e1; quiz e13-4. PubMed ID: 21070781
[TBL] [Abstract][Full Text] [Related]
35. Renal effects of long-term treatment with 5-aminosalicylic acid.
Patel H; Barr A; Jeejeebhoy KN
Can J Gastroenterol; 2009 Mar; 23(3):170-6. PubMed ID: 19319380
[TBL] [Abstract][Full Text] [Related]
36. Methotrexate in chronic active Crohn's disease: a double-blind, randomized, Israeli multicenter trial.
Oren R; Moshkowitz M; Odes S; Becker S; Keter D; Pomeranz I; Shirin H; Reisfeld I; Broide E; Lavy A; Fich A; Eliakim R; Patz J; Villa Y; Arber N; Gilat T
Am J Gastroenterol; 1997 Dec; 92(12):2203-9. PubMed ID: 9399753
[TBL] [Abstract][Full Text] [Related]
37. Cyclosporine for induction of remission in Crohn's disease.
McDonald JW; Feagan BG; Jewell D; Brynskov J; Stange EF; Macdonald JK
Cochrane Database Syst Rev; 2005 Apr; (2):CD000297. PubMed ID: 15846602
[TBL] [Abstract][Full Text] [Related]
38. Review article: chronic active disease and maintaining remission in Crohn's disease.
Kamm MA
Aliment Pharmacol Ther; 2004 Oct; 20 Suppl 4():102-5. PubMed ID: 15352904
[TBL] [Abstract][Full Text] [Related]
39. Oral mesalazine for the treatment of Crohn's disease: clinical efficacy with respect to pharmacokinetic properties.
Tromm A; Griga T; May B
Hepatogastroenterology; 1999; 46(30):3124-35. PubMed ID: 10626173
[TBL] [Abstract][Full Text] [Related]
40. Inducing and maintaining remission in ulcerative colitis: role of high-dose, extended-release mesalamine.
Kao J; Kwok K; Das KM
J Clin Gastroenterol; 2010 Sep; 44(8):531-5. PubMed ID: 20495466
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
